Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy
"The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future," said Jacob Thaysen, chief executive officer of Illumina. "Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling." This transaction builds on a co-development agreement Illumina established with SomaLogic in December 2021 to bring the SomaScan® Proteomics Assay onto Illumina's high-throughput next-generation-sequencing (NGS) platforms. Illumina Protein Prep is currently in use with nearly 40 early-access customers globally and will become available to all customers starting in the third quarter of 2025. Combining SomaLogic's proteomics technology with Illumina's scalable NGS ecosystem, DRAGEN™ software, and Illumina Connected Multiomics will accelerate the technology development roadmap for proteomics and reduce time and cost of proteomic research.
"We are taking the scalability of NGS into proteomics," continued Thaysen. "Illumina will remain an open, accessible, and enabling NGS platform. The Company is committed to maintaining and supporting its existing proteomics partnerships as well as continuing to develop the sequencing ecosystem and supporting a wide variety of multiomics solutions." Scientific evidence* presented over the past year demonstrates the strength of SomaLogic's proteomics offerings in the areas of plexity, scalability, and technical reproducibility. In addition, researchers can generate significant and pivotal insights with high sensitivity, high throughput, and thousands of protein markers in a single experiment.
SomaLogic has approximately 250 employees worldwide working in commercial, R&D, lab operations, manufacturing, and other roles. The company's Boulder, Colorado, facilities—including a CLIA- and CAP-certified lab, office, and manufacturing space—will be part of the purchase. SomaLogic has a global footprint serving customers.
This transaction brings SomaLogic's aptamer-based affinity proteomics platform into Illumina's portfolio, enhancing Illumina's presence in a high-growth area within the proteomics market. The kitted NGS-based panels business will add a high-margin consumables revenue stream. Based on the projected closing date, Illumina expects this business to become profitable in 2027 on a non-GAAP operating income basis, and for non-GAAP operating margins to be in line with Illumina in 2028.
Completion of the transaction is subject to customary closing conditions, including the receipt of required regulatory clearance. The parties intend to make the necessary filing under the Hart-Scott-Rodino Act in the United States in due course. Illumina expects to close the transaction in the first half of 2026. Until then, the companies will continue to operate as separate and independent entities.
Goldman Sachs and Co. LLC is serving as financial advisor and Cravath, Swaine & Moore LLP is serving as legal advisor to Illumina. Centerview Partners LLC is serving as financial advisor to Standard BioTools, and Freshfields LLP and Richards, Layton & Finger P.C. are serving as its legal counsel. UBS Investment Bank is serving as financial advisor to the Special Committee of the Standard BioTools Board of Directors.
Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the completion of the proposed transaction on the anticipated terms and timeline, or at all, including the ability of the parties to obtain required regulatory clearance—such as under the Hart-Scott-Rodino Act in the United States or from government authorities that may have or assert jurisdiction outside the United States—and to satisfy other conditions to closing; (ii) the future conduct and growth of the business and the markets in which we operate, including the proteomics market; (iii) the success of products and services competitive with our own; (iv) our ability to successfully integrate SomaLogic into our existing operations and SomaLogic's technology and products into our portfolio; (v) our ability to sell SomaLogic's products and further develop SomaLogic's technology; (vi) our ability to successfully manage partner and customer relationships in the proteomics market; (vii) our ability to manufacture robust instrumentation and consumables including SomaLogic's products; (viii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (ix) challenges inherent in developing, manufacturing, and launching new products and services; and (x) customer uptake of, and satisfaction with, new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
*References: 1. Rooney MR, Chen J, Ballantyne CM, et al. Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink. medRxiv. Preprint posted online July 12, 2024. doi:10.1101/2024.07.11.24310161 2. Kirsher DY, Chand S, Phong A, Nguyen B, Szoke BG, Ahadi S. The current landscape of plasma proteomics: technical advances, biological insights, and biomarker discovery. bioRxiv. Preprint posted online February 19, 2025. doi: 10.1101/2025.02.14.638375 Logo - https://mma.prnewswire.com/media/2718501/illumina_Logo.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
US stock market prediction: Will Nasdaq, S&P 500, Dow Jones slip or rise on Monday? Check lucrative stocks
US Stock Market indexes -- Dow Jones, S&P 500, and Nasdaq -- will look to maintain its positive run at the Wall Street. However, investors will keep close eyes on the Federal Reserve and Fed Chair Jerome Powell to check whether there will be interest rate cut or not. U.S. stocks edged back from their record levels on Friday in a quiet finish to another winning week. The S&P 500 slipped 0.3 per cent from the all-time high it set the day before, as it closed its fourth winning week in the last five. The Dow Jones Industrial Average flirted with its own record, which was set in December, before ending just below the mark with a rise of 34 points, or 0.1 per cent. The Nasdaq composite dipped 0.4 per cent, though it's still near its record set on Wednesday. The U.S. stock market reached all-time highs this past week as expectations built that the Federal Reserve will deliver a cut to interest rates at its next meeting in September. Lower rates can boost investment prices and the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment, but they also risk worsening inflation. US Stock Market Outlook Companies likely to benefit most from lower borrowing costs have been among the big winners in recent Wall Street trading, said Andrew Slimmon, head of Applied Equity Advisors at Morgan Stanley Asset Management. Shares of leading homebuilders such as PulteGroup, Lennar, and D.R. Horton are up between 4.2 per cent and 8.8 per cent in the last week, as of midday Friday, thanks largely to the recent drop in mortgage lending rates. Live Events Their gains trounced the 1 per cent rally in the Standard & Poor's 500 index over the last week. The group has outpaced the broader market more dramatically over the last month, with gains of 15 per cent to 22 per cent compared to 3.3 per cent for the S&P 500. But their future gains hinge on mortgage rates continuing to fall, something that a recent uptick in 10-year Treasury bond yields puts into question. FAQs Q1. What are US Stock Market indexes? A1. US Stock Market indexes are Dow Jones, S&P 500, and Nasdaq. Q2. Which stocks have gone up? A2. Shares of leading homebuilders such as PulteGroup, Lennar, and D.R. Horton are up between 4.2 per cent and 8.8 per cent in the last week, as of midday Friday, thanks largely to the recent drop in mortgage lending rates.
Economic Times
3 hours ago
- Economic Times
He said no to Steve Jobs' advice, and lost his shot at becoming the world's first trillionaire - who is he?
Back in 1976, a young Steve Jobs offered his former Atari boss the chance to buy one-third of Apple for just $50,000. He said no. Nearly 50 years later, that decision stands as one of the most jaw-dropping missed opportunities in Silicon Valley history — a deal that could have made him nearly a trillionaire. Steve Jobs' First Silicon Valley Boss Passed on Apple for $50,000 — When Steve Jobs and Steve Wozniak were trying to get Apple off the ground in 1976, they turned to someone Jobs trusted — his former boss at Atari, Nolan Bushnell. Jobs offered him a chance to buy a one-third stake in Apple for just $50,000. Bushnell, already busy running Atari and expanding into new ventures, declined. At the time, the offer seemed like a gamble on two kids working out of a garage. Today, that same stake would be valued at nearly $1 trillion, making it one of the greatest missed opportunities in Silicon Valley's history. In 1976, Steve Jobs walked into his boss's office with an offer that seemed modest at the time: invest $50,000 for a one-third stake in Apple Computer. The man across the table was Nolan Bushnell, cofounder of Atari and the so-called 'father of video games.' Bushnell declined. Nearly half a century later, that rejected deal would have translated into close to $1 trillion, making him wealthier than any single entrepreneur alive today. Bushnell wasn't just Jobs' employer; he was one of his earliest mentors. Jobs had worked at Atari in the mid-1970s, a period that honed his design instincts and taught him the value of merging technology with play. Yet when Jobs and Steve Wozniak tried to bring him in as an early backer of Apple, Bushnell passed. Speaking to ABC Australia in 2015, Bushnell explained: 'It seemed like a lot of money. And I was so busy with Atari. I had other priorities.' Bushnell later doubled down on that sentiment, telling Fortune in 2025 that even though the lost fortune is staggering, he holds no regrets. In his words, becoming 'uber, uber, uber rich' wasn't the only path to fulfillment. To put the numbers in perspective: Apple's market capitalization as of August 2025 is hovering around $2.8 trillion (Nasdaq data). as of August 2025 is hovering around (Nasdaq data). A one-third share would therefore equal approximately $930 billion . would therefore equal approximately . For comparison, that's larger than the entire GDP of Switzerland ($905 billion, IMF 2024). Had Bushnell taken the offer, he would have eclipsed the net worth of today's richest individuals — Elon Musk ($232 billion), Jeff Bezos ($195 billion), and Bernard Arnault ($187 billion, Forbes Billionaires List 2025). At first glance, this story reads like one of history's great financial blunders. But looking closer, it's also a reminder of how timing, perspective, and personal values shape business decisions. In 1976, Apple wasn't Apple. It was two young men in a garage, pitching hand-assembled circuit boards. Atari was already a global gaming phenomenon, and Bushnell was expanding into family entertainment through Chuck E. Cheese. Betting on Jobs and Wozniak wasn't an obvious 'slam dunk.' Bushnell himself has noted in interviews that constantly chasing every investment would have distracted him from building his own legacy. Atari pioneered the arcade revolution. Chuck E. Cheese blended tech with entertainment in ways that shaped American childhoods. While he may have missed out on a trillion-dollar payday, he didn't miss out on cultural influence. From an investor's perspective, the Bushnell story underscores a brutal truth: most world-changing companies don't look obvious at the start. In 1976, $50,000 for Apple seemed speculative. Today, missing out on early tech bets is a recurring theme in Silicon Valley. Consider: Ronald Wayne , Apple's forgotten cofounder, sold his 10% stake for $800 in 1976. That stake would now be worth $280 billion . , Apple's forgotten cofounder, sold his in 1976. That stake would now be worth . Yahoo! had the chance to buy Google for $1 million in 1998. They passed. Google's market cap is now $2.1 trillion . had the chance to buy Google for in 1998. They passed. Google's market cap is now . Blockbuster laughed off Netflix's $50 million sale pitch in 2000. Netflix is worth $235 billion today, while Blockbuster has vanished. These cautionary tales reinforce that early innovation often looks like a gamble, not a guarantee. For investors, the Bushnell-Apple saga is a lesson in humility: even seasoned entrepreneurs with vision can miss the next big thing. For entrepreneurs, it's a reminder that rejection doesn't kill potential. Jobs and Wozniak didn't fold when Bushnell said no; they doubled down until the world had to listen. For ordinary readers, it's also a useful lens into decision-making. Bushnell might have missed a trillion-dollar windfall, but he avoided the 'golden handcuffs' of wealth that could have reshaped his life in ways he didn't want. Not every no is a mistake, and not every yes guarantees peace of mind. Almost fifty years on, the story remains one of Silicon Valley's most powerful what-ifs. If Bushnell had invested, Apple's trajectory might not have been the same. He could have influenced strategy, direction, or culture — for better or worse. In the end, his refusal gave Jobs and Wozniak complete independence, which arguably allowed Apple to grow into the uncompromising company it became. And perhaps that's the hidden legacy: one man's no helped preserve Apple's DNA. Nolan Bushnell turned down one of the greatest deals in corporate history — a third of Apple for $50,000. On paper, it cost him nearly $1 trillion. In reality, it gave Steve Jobs and Apple the autonomy to shape the world on their own termsQ1: Who was Steve Jobs' first Silicon Valley boss who turned down Apple's $50,000 offer? A1: It was Nolan Bushnell, the founder of Atari. Q2: How much would a $50,000 investment in Apple be worth today? A2: Nearly $1 trillion in 2025.
Time of India
4 hours ago
- Time of India
Kyivstar CEO says Russia-Ukraine peace deal would boost value after historic US listing
By Gianluca Lo Nostro and Leo Marchandon A peaceful resolution to the war between Russia and Ukraine would boost the value of Ukrainian mobile operator Kyivstar "quite significantly", its CEO Oleksandr Komarov said on Friday ahead of the company's stock market listing in New York. Kyivstar's shares will begin trading on the Nasdaq later on Friday, becoming the first Ukraine-based company listed on a U.S. stock exchange. The listing coincides with a summit between U.S. President Donald Trump and Russian President Vladimir Putin in Alaska, a meeting closely watched by Ukraine and European nations as a potential turning point in peace negotiations. "We will be the best asset for the international investment community to invest in Ukraine, to invest in the Ukrainian recovery, to invest in the Ukrainian support," Komarov told Reuters in an interview. Komarov said the company chose Nasdaq, where its parent VEON is also listed, over London or Warsaw because it was even more important to "strengthen the link between the United States and Ukraine rather than between Ukraine and Europe." The company has deepened its U.S. ties during the conflict, appointing former U.S. Secretary of State Mike Pompeo to its board and signing a deal with Elon Musk's Starlink for satellite services. Kyivstar is the biggest mobile operator in Ukraine with 24 million subscribers. Founded in 1994, it became part of Veon in 2010. Apart from telecoms, it owns digital health platform Helsi and ride-hailing firm Uklon. VEON has pitched the listing as an opportunity for foreign investors to bet on Ukraine's reconstruction. But its success hinges in part on a peace deal being achieved. Komarov said that the first few weeks of trading will be extremely volatile. When asked if the outcome of the IPO depends on political developments, he said the volatile external environment was already incorporated in Kyivstar's valuation. Kyivstar, which has been given a pro forma valuation of $2.3 billion, carried out the listing by merging with fintech entrepreneur Betsy Cohen's special purpose acquisition company (SPAC). The company raised $178 million. Reuters earlier reported Kyivstar expected up to $200 million. VEON will retain a majority stake in the mobile operator. Komarov said his firm's Nasdaq debut showed what Ukrainian companies could accomplish by accessing international markets and that prominent Ukrainian businessmen have spoken to him in recent months to hear about Kyivstar's listing strategy. "This is one of the dimensions of our integration into the Western world that should be developed and should be supported," he said.
